LPL Financial
ACTU

LPL Financial’s Actuate Therapeutics ACTU Stock Holding History

LPL Financial’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.5K Hold
12,965
– – ﹤0.01% 5817
2025
Q4 		$79.3K Sell
12,965
-3,250
-20% -$22.3K ﹤0.01% 5647
2025
Q3 		$108K Sell
16,215
-2,490
-13% -$18.1K ﹤0.01% 5499
2025
Q2 		$114K Buy
+18,705
New +$163K ﹤0.01% 5240

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial's ACTU Position: Q1 2026 in Review

LPL Financial held its Actuate Therapeutics (ACTU) position steady in Q1 2026 at 12,965 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5817.

LPL Financial first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $114K in Q2 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • LPL Financial held 12,965 shares of Actuate Therapeutics worth $35.5K as of Q1 2026.
  • LPL Financial left its Actuate Therapeutics share count unchanged in Q1 2026.
  • Actuate Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5817 holding.
  • LPL Financial first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • LPL Financial's Actuate Therapeutics position peaked at $114K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.